Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

### Corporate Overview

**Highlights**
- Clinical Stage Antiviral Company
- Proprietary Drug Discovery Platform
- Merck Influenza Collaboration

**Target Diseases**
- Influenza
- Hepatitis
- Coronavirus (COVID-19)
- Norovirus (Gastroenteritis)

### Strategy Directed at Advancing Programs and Growing Value

- Advancing preclinical COVID-19 Coronavirus program leveraging patent rights and compounds recently acquired from Kansas State University Research Foundation (KSURF)
- Ongoing collaboration with Merck has accelerated influenza A/B development program
- Continue to progress an innovative pipeline for Influenza, Hep C, COVID-19 and Norovirus gastroenteritis
- Form additional strategic collaborations and partnership

### Robust Development Pipeline

<table>
<thead>
<tr>
<th>Program</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2a</th>
<th>Phase 2b</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis C (HCV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-31244 – University of MD (Pan-genotypic NS5B NNI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-42344 (Influenza A PB2 Inhibitor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza A/B Inhibitor</td>
<td>In collaboration with</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronairus (COVID-19)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Replication and Protease Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norovirus (Gastroenteritis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Replication and Protease Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Management Team**

Gary Wilcox, Ph.D.
Chairman and Chief Executive Officer
Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis

Sam Lee, Ph.D.
President
Over 25 years of anti-infective drug discovery research experience and played a key role in the early development of phosphoinositide 3-kinase (PI3K) delta inhibitors

James J. Martin, MBA, CPA
Chief Financial Officer
Over 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies

**Board of Directors**

Gary Wilcox, Ph.D.
Chairman and Chief Executive Officer

Roger Kornberg, Ph.D.
Director, Chief Scientist, Chairman of Scientific Advisory Board

Phillip Frost, M.D.
Director

Anthony Japour, M.D.
Director

Steve Rubin
Director

**Share Information**

- NASDAQ: COCP
- Share Price*: $.90
- Market Cap*: $46.8M
- Shares Outstanding: 52.1M

*As of May 04, 2020

**Investor Contact:**

JTC
Jenene Thomas
833.475.8247
cocop@jtcir.com
Technology and Drug Discovery Platform

- Fully-optimized operations from expression through high resolution X-ray data
- Stringent quality oversight of procedures for crystal production
- High throughput X-ray data collection and computation methods
- Large-scale crystal production capabilities

CC-31244: HCV Non-Nucleoside Inhibitor (NNI)

Next Generation Combination Therapy
- Potential best-in-class HCV NNI with a strong profile
  - Broad spectrum, potent NS5B polymerase inhibitor
  - High barrier to drug resistance
  - Effective against known NNI drug resistant variants
  - Liver targeting
  - Novel mechanism of action

Influenza A/B Inhibitor: Cocrystal/Merck Collaboration Program
- Broad spectrum, potent dual influenza A/B preclinical lead will be developed
  - Result of Cocrystal’s drug discovery platform technology
  - Binds to highly conserved site of influenza A and B replication complex
  - Expected to be active against seasonal, pandemic and drug resistant influenza A and B strains
  - Expected to exhibit superior drug resistant profile

COVID-19: Development of Novel Antiviral Therapies
- Potential to be effective treatment for COVID-19 (SARS-CoV-2)
- Develop broad spectrum COVID-19 (SARS-CoV-2) inhibitors using proprietary platform technology
- Targeting viral replication complex and protease
- Potential first-in-class therapeutic and prophylactic treatment

CC-42344: Influenza PB2 Lead
- Binds to the highly conserved m7GTP binding pocket of PB2
- Exhibits broad spectrum activity against seasonal and pandemic influenza strains
- Favorable preclinical safety profile and pharmacokinetic properties
- Multiple routes of administration (oral, inhalation, IM)
  - Existing drugs Tamiflu® and Xofluza™ limited to oral administration

Norovirus Program
- Potential first therapy
- Potent and broad-spectrum polymerase and protease inhibitors
- Structure-based lead discovery ongoing
- Licensed potent, broad spectrum protease inhibitors from KSURF